Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:0571-86130357     Add to Favorites | Online Feedback 中文
新闻中心 / News Center
Lancet Oncology: The Phase III clinical research results of Icotinib was published in full text
Form: betta   Date: 2013-08-13

        On August 13th 2013, the Phase III ICOGEN research results of Icotinib, of which Professor Shi Yuankai from Cancer Hospital Chinese Academy of Medical Sciences and Professor Zhang Li from Sun Yat-Sen University Cancer Center were the co-first authors and Academician of Chinese Academy of Sciences, Sun Yan was the corresponding author, were officially published in world-renowned academic journal, Lancet Oncology(http://www.thelancet.com/journals/lanonc/article /PIIS1470-2045(13)70355-3/abstract).


Prev: The Company successfully passed the ISO14001/18001 Certification
Next: China’s Innovative drug, Icotinib was included in the 2012 Global New Drugs Research and Development Directory for the first time